Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients

Mitotane is considered to be the drug of choice for patients with inoperable, recurrent and metastatic adrenocortical carcinoma, although a favourable effect of this drug on survival has never been documented. We evaluated the efficacy of mitotane treatment of 96 patients with adrenocortical carcinoma followed up in our department between 1959 and 1992. Complete tumour resection was the goal of the initial treatment. Mitotane treatment was classified according to serum trough concentrations on maintenance therapy: low (< 14 mg l-1) or high (> or = 14 mg l-1). Total tumour resection was feasible in 47 patients (49%), and subtotal resection was performed in 37 patients (39%). Patients who underwent total tumour resection survived significantly longer than those who did not (P < 0.001). Adjuvant mitotane therapy (n = 11) did not influence survival after total resection. Sixty-two patients were given mitotane treatment at some time during their illness, only 30 of whom reached high maintenance serum levels. Mitotane treatment with high serum levels had an independently favourable influence on patient survival, using univariate (P < 0.01) and multivariate analysis (P = 0.01). Mitotane treatment resulting in low serum levels was tantamount to not giving mitotane at all. We conclude that mitotane treatment in adrenocortical carcinoma is effective only when high serum levels can be achieved.

Abstract licence: CC BY

1. 1.

   Becker D., Schumacher O. P. o,p'DDD therapy in invasive adrenocortical carcinoma. Ann Intern Med. 1975;82(5):677-679.

   Not in our library10.7326/0003-4819-82-5-677 (opens in a new tab)

2. 2.

   Bertagna C., Orth D. N. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med. 1981;71(5):855-875.

   Not in our library10.1016/0002-9343(81)90384-3 (opens in a new tab)

3. 3.

   Eriksson B., Oberg K., Curstedt T., Hemmingsson A., Johansson H., Lindh E., Lindgren P. G., Thuomas K. A., Wilander E., Akerström G. Treatment of hormone-producing adrenocortical cancer with o,p'DDD and streptozocin. Cancer. 1987;59(8):1398-1403.

   Not in our library10.1002/1097-0142(19870415)59:8<1398::aid-cncr2820590803>3.0.co;2-z (opens in a new tab)

4. 4.

   Haak H. R., van Seters A. P., Moolenaar A. J. Mitotane therapy of adrenocortical carcinoma. N Engl J Med. 1990;323(11):758-758.

   Not in our library10.1056/nejm199009133231115 (opens in a new tab)

5. 5.

   Harris D. T., Mastrangelo M. J. Theory and application of early systemic therapy. Semin Oncol. 1991;18(6):493-503.

   Not in our library

6. 6.

   Hutter A. M., Kayhoe D. E. Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med. 1966;41(4):572-580.

   Not in our library10.1016/0002-9343(66)90219-1 (opens in a new tab)

7. 7.

   Hutter A. M., Kayhoe D. E. Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients. Am J Med. 1966;41(4):581-592.

   Not in our library10.1016/0002-9343(66)90220-8 (opens in a new tab)

8. 8.

   Jarabak J., Rice K. Metastatic adrenal cortical carcinoma. Prolonged regression with mitotane therapy. JAMA. 1981;246(15):1706-1707.

   Not in our library

9. 9.

   Johnson D. H., Greco F. A. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer. 1986;58(10):2198-2202.

   Not in our library10.1002/1097-0142(19861115)58:10<2198::aid-cncr2820581006>3.0.co;2-a (opens in a new tab)

10. 10.

    LIPSETT M. B., HERTZ R., ROSS G. T. CLINICAL AND PATHOPHYSIOLOGIC ASPECTS OF ADRENOCORTICAL CARCINOMA. Am J Med. 1963;35:374-383.

    Not in our library10.1016/0002-9343(63)90179-7 (opens in a new tab)

11. 11.

    Lubitz J. A., Freeman L., Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA. 1973;223(10):1109-1112.

    Not in our library

12. 12.

    Luton J. P., Cerdas S., Billaud L., Thomas G., Guilhaume B., Bertagna X., Laudat M. H., Louvel A., Chapuis Y., Blondeau P. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322(17):1195-1201.

    Not in our library10.1056/nejm199004263221705 (opens in a new tab)

13. 13.

    MACFARLANE D. A. Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl. 1958;23(3):155-186.

    Not in our library

14. 14.

    Moolenaar A. J., Niewint J. W., Oei I. T. Estimation of o,p'-DDD in plasma by gas-liquid chromatography. Clin Chim Acta. 1977;76(2):213-218.

    Not in our library10.1016/0009-8981(77)90098-5 (opens in a new tab)

15. 15.

    Moolenaar A. J., van Slooten H., van Seters A. P., Smeenk D. Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment. Cancer Chemother Pharmacol. 1981;7(1):51-54.

    Not in our library10.1007/bf00258213 (opens in a new tab)

16. 16.

    Samaan N. A., Hickey R. C. Adrenal cortical carcinoma. Semin Oncol. 1987;14(3):292-296.

    Not in our library

17. 17.

    Venkatesh S., Hickey R. C., Sellin R. V., Fernandez J. F., Samaan N. A. Adrenal cortical carcinoma. Cancer. 1989;64(3):765-769.

    Not in our library10.1002/1097-0142(19890801)64:3<765::aid-cncr2820640333>3.0.co;2-i (opens in a new tab)

18. 18.

    van Seters A. P., Moolenaar A. J. Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol (Copenh). 1991;124(5):526-533.

    Not in our library10.1530/acta.0.1240526 (opens in a new tab)

19. 19.

    van Slooten H., Moolenaar A. J., van Seters A. P., Smeenk D. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol. 1984;20(1):47-53.

    Not in our library10.1016/0277-5379(84)90033-6 (opens in a new tab)

20. 20.

    van Slooten H., van Oosterom A. T. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep. 1983;67(4):377-379.

    Not in our library

• EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity · 2022

  Not checked

• Clinical results of the use of mitotane for adrenocortical carcinoma · 2000

  Not checked

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.